Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Non-Current Assets (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of Non-Current Assets readings, the most recent being $224457.0 for Q1 2026.

  • On a quarterly basis, Non-Current Assets fell 58.63% to $224457.0 in Q1 2026 year-over-year; TTM through Jan 2026 was $1.4 million, a 27.14% decrease, with the full-year FY2025 number at $266201.0, down 55.15% from a year prior.
  • Non-Current Assets hit $224457.0 in Q1 2026 for Pharma-Bio Serv, down from $266201.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $2.7 million in Q1 2023 to a low of $224457.0 in Q1 2026.
  • Median Non-Current Assets over the past 5 years was $542611.0 (2025), compared with a mean of $685533.2.
  • Biggest five-year swings in Non-Current Assets: soared 153.05% in 2023 and later crashed 82.87% in 2024.
  • Pharma-Bio Serv's Non-Current Assets stood at $707243.0 in 2022, then decreased by 29.17% to $500964.0 in 2023, then grew by 18.47% to $593477.0 in 2024, then plummeted by 55.15% to $266201.0 in 2025, then fell by 15.68% to $224457.0 in 2026.
  • The last three reported values for Non-Current Assets were $224457.0 (Q1 2026), $266201.0 (Q4 2025), and $429922.0 (Q3 2025) per Business Quant data.